News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
ASX Small Caps and IPO Weekly Wrap: Everything sank except gold. What a mess.
News
Market Highlights: Fed comments trigger Wall Street selloff; and where is gold headed from here?
Health & Biotech
Weed Week: Medicinal cannabis will be here no matter what; and recent ASX pot winners
Health & Biotech
Weed Week: Blow to cannabis as Thailand backpedals on weed law; and recent ASX pot stock winners
News
In Case You Missed It: Spodumene finds and Google Cloud Partner designation
Health & Biotech
ASX Health Stocks: Emyria surges 19pc after granting of ‘Authorised Prescriber’ status by TGA
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Health & Biotech
ASX Health Stocks: Amplia’s pancreatic cancer trial gets boost; Emyria’s MDMA therapy is one step closer
Health & Biotech
ASX Health Stocks: Telix tumbles 17pc, Emyria to import MDMA after approval in Canada
Health & Biotech
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
News
ASX Small Caps & IPO Weekly Wrap: ASX dips 2.2pc and everyone Torqued like a pirate at Penzance
News
Rise and Shine: Everything you need to know before the ASX opens
News
In Case You Missed It: Rare earths on the rise, and coal seam gas pilot spudded
News
ASX Small Caps Lunch Wrap: Who else is feeling the Real Estate rage today?
News
Top 10 at 11: Emyria soars on funding news, and loads of tasty stuff unearthed in Canada.
News